
Orthofix International (OFIX) Stock Forecast & Price Target
Orthofix International (OFIX) Analyst Ratings
Bulls say
Orthofix Medical Inc. has raised its long-term net sales compounded annual growth rate (CAGR) target to 6.5%-7.5%, reflecting a positive outlook for future revenue growth. The company reported an adjusted EBITDA of $23.9 million, marking a year-over-year increase and exceeding consensus estimates, alongside a notable expansion in adjusted EBITDA margins. Additionally, the strong performance in the global spine segment, with a 12% increase in Spine Fixation and a robust 30% rise in the enabling technology segment, further underscores Orthofix's market leadership and potential for continued growth in the orthopedic and spine solutions market.
Bears say
Orthofix Medical Inc. has faced significant operational challenges, particularly highlighted by the discontinuation of the M6-C and M6-L artificial disc product lines, which will contribute to a loss of $23.4 million in sales for 2024 and has negatively impacted EBITDA margins. Additionally, the company is under pressure from increasing competition from larger and better-financed rivals, as well as potential execution risks associated with the merger with SeaSpine, which may hinder its sales momentum and overall performance. Furthermore, a shift in the healthcare landscape, including decreasing reimbursement rates and heightened regulatory scrutiny, poses ongoing risks that could adversely affect Orthofix's earnings potential and market positioning.
This aggregate rating is based on analysts' research of Orthofix International and is not a guaranteed prediction by Public.com or investment advice.
Orthofix International (OFIX) Analyst Forecast & Price Prediction
Start investing in Orthofix International (OFIX)
Order type
Buy in
Order amount
Est. shares
0 shares